The development of a novel class of pharmacodynamic hybrids that inhibits COX-2 isoform is reported. These molecules display enhanced nitric oxide releasing properties due to the presence of an ionisable moiety. The in vivo analgesic/anti-inflammatory activity was maintained in relation to the parent compounds
The development of the coxib family has represented a stimulating approach in the treatment of infla...
A new group of hybrid nitric oxide-releasing anti-inflammatory drugs (NONO-coxibs), in which an O 2-...
A series of 3-substituted 1,5-diarylpyrroles bearing a nitrooxyalkyl side chain linked to different ...
The development of a novel class of pharmacodynamic hybrids that inhibits COX-2 isoform is reported....
We report herein the development, synthesis, physicochemical and pharmacological characterization of...
We report herein the development, synthesis, physicochemical and pharmacological characterization of...
The design of compounds that are able to inhibit cyclooxygenase (COX) and to release nitric oxide (N...
Herein we report the synthesis, biological evaluation, and docking analysis of a class of cyclooxyge...
The design of compounds able to combine the selective inhibition of cyclooxygenase-2 (COX-2) with th...
The design of compounds that are able to inhibit cyclooxygenase (COX) and to release nitric oxide (N...
Herein we report the synthesis, biological evaluation, and docking analysis of a class of cyclooxyge...
This study includes design and synthesis of new non-steroidal anti-inflammatory agents (NSAIDs) with...
Many years of work have been invested in the identification of potent and selective COX-2 inhibitors...
The pharmacotherapy of complex pathological states at the cardiovascular level often requires differ...
The important role of cyclooxygenase-2 (COX-2) in the pathogenesis of inflammation and side effect l...
The development of the coxib family has represented a stimulating approach in the treatment of infla...
A new group of hybrid nitric oxide-releasing anti-inflammatory drugs (NONO-coxibs), in which an O 2-...
A series of 3-substituted 1,5-diarylpyrroles bearing a nitrooxyalkyl side chain linked to different ...
The development of a novel class of pharmacodynamic hybrids that inhibits COX-2 isoform is reported....
We report herein the development, synthesis, physicochemical and pharmacological characterization of...
We report herein the development, synthesis, physicochemical and pharmacological characterization of...
The design of compounds that are able to inhibit cyclooxygenase (COX) and to release nitric oxide (N...
Herein we report the synthesis, biological evaluation, and docking analysis of a class of cyclooxyge...
The design of compounds able to combine the selective inhibition of cyclooxygenase-2 (COX-2) with th...
The design of compounds that are able to inhibit cyclooxygenase (COX) and to release nitric oxide (N...
Herein we report the synthesis, biological evaluation, and docking analysis of a class of cyclooxyge...
This study includes design and synthesis of new non-steroidal anti-inflammatory agents (NSAIDs) with...
Many years of work have been invested in the identification of potent and selective COX-2 inhibitors...
The pharmacotherapy of complex pathological states at the cardiovascular level often requires differ...
The important role of cyclooxygenase-2 (COX-2) in the pathogenesis of inflammation and side effect l...
The development of the coxib family has represented a stimulating approach in the treatment of infla...
A new group of hybrid nitric oxide-releasing anti-inflammatory drugs (NONO-coxibs), in which an O 2-...
A series of 3-substituted 1,5-diarylpyrroles bearing a nitrooxyalkyl side chain linked to different ...